Leonard S. Schleifer - 31 Dec 2025 Form 4 Insider Report for REGENERON PHARMACEUTICALS, INC. (REGN)

Signature
/s/ Leonard S. Schleifer
Issuer symbol
REGN
Transactions as of
31 Dec 2025
Net transactions value
-$22,058,611
Form type
4
Filing time
05 Jan 2026, 17:53:17 UTC
Previous filing
11 Dec 2025

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
SCHLEIFER LEONARD S Bd. Co-Chair, President & CEO, Director 777 OLD SAW MILL RIVER ROAD, TARRYTOWN /s/ Leonard S. Schleifer 05 Jan 2026 0001218629

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction REGN Common Stock Options Exercise $0 +28,570 +13% $0.000000 243,093 31 Dec 2025 Direct
transaction REGN Common Stock Tax liability $22,058,611 -28,570 -12% $772.09 214,523 31 Dec 2025 Direct
holding REGN Common Stock 127,484 31 Dec 2025 By 2024 GRAT
holding REGN Common Stock 300,000 31 Dec 2025 By 2025 GRAT
holding REGN Common Stock 5,989 31 Dec 2025 By 401(k) Plan
holding REGN Common Stock 39,985 31 Dec 2025 By Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction REGN 2020 Performance Stock Units Options Exercise $0 -28,570 -4.6% $0.000000 595,077 31 Dec 2025 Common Stock 28,570 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each performance restricted stock unit ("PSU") represents a contingent right to receive one share of Company stock. These PSUs were earned during the applicable five-year performance period and vested on December 31, 2025 but remain subject to a mandatory holding period of three years after vesting, which ends early upon the reporting person's death or disability or a change in control of the Company.